MAFLanreotide Prolonged-Release Solution For Injection In Pre-Filled Syringe 60 mg, 90 mg, 120 mg
1) For the reduction of symptoms associated with carcinoid syndrome.
2) For the improvement of symptoms associated with acromegaly.
3) Treatment of acromegaly in patients with abnormal levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) after surgery and/or radiotherapy or in patients who require medical treatment.
4) Treatment of neuroendocrine tumours of gastrointestinal or pancreatic origin.